Natixis trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 46.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,602 shares of the biopharmaceutical company’s stock after selling 17,309 shares during the period. Natixis’ holdings in Amicus Therapeutics were worth $295,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of FOLD. Carillon Tower Advisers Inc. bought a new stake in Amicus Therapeutics in the fourth quarter worth approximately $26,756,000. Lord Abbett & CO. LLC bought a new stake in Amicus Therapeutics in the first quarter worth approximately $22,662,000. BlackRock Inc. grew its position in Amicus Therapeutics by 10.1% in the first quarter. BlackRock Inc. now owns 15,090,252 shares of the biopharmaceutical company’s stock worth $226,957,000 after acquiring an additional 1,378,155 shares in the last quarter. Millennium Management LLC bought a new stake in Amicus Therapeutics in the fourth quarter worth approximately $18,974,000. Finally, Sphera Funds Management LTD. grew its position in Amicus Therapeutics by 67.8% in the first quarter. Sphera Funds Management LTD. now owns 1,845,704 shares of the biopharmaceutical company’s stock worth $27,759,000 after acquiring an additional 745,704 shares in the last quarter.
In other Amicus Therapeutics news, SVP Kurt J. Andrews sold 5,000 shares of the stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $14.27, for a total transaction of $71,350.00. Following the transaction, the senior vice president now owns 45,469 shares of the company’s stock, valued at $648,842.63. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Hung Do sold 25,000 shares of the stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $16.72, for a total transaction of $418,000.00. Following the transaction, the insider now directly owns 396,771 shares in the company, valued at approximately $6,634,011.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 140,000 shares of company stock worth $2,132,800. 2.90% of the stock is currently owned by insiders.
Shares of Amicus Therapeutics opened at $15.49 on Wednesday, Marketbeat reports. The company has a quick ratio of 4.15, a current ratio of 4.21 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $2.89 billion, a PE ratio of -5.30 and a beta of 1.53. Amicus Therapeutics, Inc. has a 1-year low of $9.53 and a 1-year high of $17.62.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.08. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $16.78 million. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. analysts anticipate that Amicus Therapeutics, Inc. will post -1.3 EPS for the current year.
A number of analysts have recently weighed in on the stock. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, May 4th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 10th. Cowen restated a “buy” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, May 8th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $19.06.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.